# Cue Biopharma (CUE) — Earnings

CUE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cue/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$2.70 |
| EPS estimate | −$3.90 |
| EPS surprise | +30.77% |
| Revenue surprise | +47.70% |
| Revenue | $3.0M |
| Revenue estimate | $2.0M |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1645460/000095017025107270/cue-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$3.90 | −$2.70 | 30.77% | $2.0M | $3.0M |
| Q1 2025 | May 12, 2025 | −$4.60 | −$5.10 | -10.87% | $1.3M | $421,000.00 |
| Q4 2024 | Mar 31, 2025 | −$2.58 | −$3.90 | -51.16% | $1.7M | $1.6M |
| Q3 2024 | Nov 14, 2024 | −$5.48 | −$5.10 | 6.85% | $1.5M | $3.3M |
| Q2 2024 | Aug 14, 2024 | −$8.40 | −$6.00 | 28.57% | $1.3M | $2.7M |
| Q1 2024 | May 9, 2024 | −$8.46 | −$7.50 | 11.35% | $1.2M | $1.7M |
| Q4 2023 | Mar 28, 2024 | −$9.00 | −$8.40 | 6.67% | $966,667.00 | $1.8M |
| Q2 2023 | Aug 8, 2023 | −$9.15 | −$8.70 | 4.92% | $907,500.00 | $1.4M |
| Q1 2023 | May 9, 2023 | −$8.33 | −$8.70 | -4.50% | $1.9M | $187,000.00 |
| Q4 2022 | Mar 21, 2023 | −$8.85 | −$11.10 | -25.42% | $103,750.00 | $151,000.00 |
| Q3 2022 | Nov 14, 2022 | −$11.30 | −$9.30 | 17.70% | $513,500.00 | $68,000.00 |
| Q2 2022 | Aug 4, 2022 | −$11.70 | −$11.10 | 5.13% | $1.1M | $26,000.00 |
| Q1 2022 | May 10, 2022 | −$12.08 | −$13.20 | -9.32% | $3.1M | $1.0M |
| Q4 2021 | Mar 16, 2022 | −$12.66 | −$7.80 | 38.39% | $1.1M | $8.3M |
| Q3 2021 | Nov 9, 2021 | −$11.55 | −$12.30 | -6.49% | $2.4M | $2.4M |
| Q1 2020 | May 7, 2020 | −$10.02 | −$14.40 | -43.71% | $1.4M | $900,000.00 |

## Frequently Asked Questions

### When did Cue Biopharma (CUE) last report earnings?

Cue Biopharma last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did CUE beat earnings estimates?

Yes. Cue Biopharma reported EPS of −$2.70 for Q2 2025 against a −$3.90 estimate — a 30.77% beat.

### How much revenue did CUE report last quarter?

Cue Biopharma reported $3.0M in revenue for Q2 2025, against a consensus estimate of $2.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).